Anne Harlan Murphy

US Patent:

6562563, May 13, 2003

Filed:

Nov 3, 1999

Appl. No.:

09/434354

Inventors:

Anne N. Murphy - Encinitas CA
William Clevenger - Oceanside CA
Sandra Eileen Wiley - San Diego CA
Alexander Y. Andreyev - San Diego CA
Luciano G. Frigeri - San Diego CA
Robert E. Davis - San Diego CA

Assignee:

Mitokor - San Diego CA

International Classification:

C12N 500

US Classification:

435 4, 435 29, 435325, 435404, 435 26, 435 14, 435 15, 536 221

Abstract:

Compositions and methods are provided for identifying agents that alter mitochondrial membrane permeability transition. The screening methods generally detect agents that alter the interaction between the mitochondrial adenine nucleotide translocator and cyclophilin D. Such agents may be used, for example, in the treatment of a variety of conditions associated with altered mitochondrial function.

US Patent:

6797467, Sep 28, 2004

Filed:

Nov 3, 2000

Appl. No.:

09/709785

Inventors:

Anne N. Murphy - Encinitas CA
William Clevenger - Oceanside CA
Sandra Eileen Wiley - San Diego CA
Alexander Y. Andreyev - San Diego CA
Luciano G. Frigeri - San Diego CA
Gonul Velicelebi - San Diego CA
Robert E. Davis - San Diego CA

Assignee:

MitoKor, Inc. - San Diego CA

International Classification:

C12Q 168

US Classification:

435 6, 435 4, 435 78, 435 26, 514588, 536 221, 800301

Abstract:

Compositions and methods are provided for identifying agents that alter mitochondrial membrane permeability transition. The screening methods generally detect agents that alter the interaction between the mitochondrial adenine nucleotide translocator and cyclophilin D. Such agents may be used, for example, in the treatment of a variety of conditions associated with altered mitochondrial function.

US Patent:

6808873, Oct 26, 2004

Filed:

Jan 16, 2001

Appl. No.:

09/765104

Inventors:

Anne N. Murphy - Encinitas CA
Amy K. Stout - Atlanta GA

Assignee:

MitoKor, Inc. - San Diego CA

International Classification:

C12Q 100

US Classification:

435 4, 435 6, 435 71, 435 911, 435 917, 536 221, 536 231, 536 243, 536 2431, 536 2432, 536 2453, 514 1

Abstract:

The invention provides methods for screening for agents that modulate mitochondrial function and in particular mitochondrial regulation of intracellular calcium. The methods may be used to detect agents that bind to a mitochondrial calcium uniporter and may also detect inhibitors or uncouplers of mitochondrial respiration. Agents identified using the screens provided herein have application in the prevention and treatment of a variety of diseases associated with abnormal mitochondrial function.

US Patent:

7005274, Feb 28, 2006

Filed:

Sep 14, 2000

Appl. No.:

09/661848

Inventors:

Robert Terkeltaub - San Diego CA, US
Anne N. Murphy - Encinitas CA, US
James A. Dykens - Encinitas CA, US
Soumitra S. Ghosh - San Diego CA, US
Robert E. Davis - San Diego CA, US

Assignee:

MIGENIX Corp. - San Diego CA
The Regents of the University of California - Oakland CA

International Classification:

C12Q 1/02

US Classification:

435 29, 435 32, 435375

Abstract:

The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

US Patent:

20040146892, Jul 29, 2004

Filed:

Oct 10, 2003

Appl. No.:

10/684232

Inventors:

Anne Murphy - Encinitas CA, US
William Clevenger - Oceanside CA, US
Sandra Wiley - San Diego CA, US
Alexander Andreyev - San Diego CA, US
Luciano Frigeri - San Diego CA, US
Gonul Velicelebi - San Diego CA, US
Robert Davis - San Diego CA, US

Assignee:

MitoKor, Inc. - San Diego CA

International Classification:

C12Q001/68
C07H021/04

US Classification:

435/006000, 435/320100, 536/023200

Abstract:

Compositions and methods are provided for identifying agents that alter mitochondrial membrane permeability transition. The screening methods generally detect agents that alter the interaction between the mitochondrial adenine nucleotide translocator and cyclophilin D. Such agents may be used, for example, in the treatment of a variety of conditions associated with altered mitochondrial function.

US Patent:

20050170329, Aug 4, 2005

Filed:

Oct 26, 2004

Appl. No.:

10/974484

Inventors:

Anne Murphy - Encinitas CA, US
Amy Stout - Atlanta GA, US

Assignee:

MIGENIX Corp. - San Diego CA

International Classification:

C12Q001/00
C12Q001/68

US Classification:

435004000, 435006000

Abstract:

The invention provides methods for screening for agents that modulate mitochondrial function and in particular mitochondrial regulation of intracellular calcium. The methods may be used to detect agents that bind to a mitochondrial calcium uniporter and may also detect inhibitors or uncouplers of mitochondrial respiration. Agents identified using the screens provided herein have application in the prevention and treatment of a variety of diseases associated with abnormal mitochondrial function.

US Patent:

20070021496, Jan 25, 2007

Filed:

Jun 29, 2005

Appl. No.:

11/172386

Inventors:

Robert Terkeltaub - San Diego CA, US
Anne Murphy - Encinitas CA, US
James Dykens - Encinitas CA, US
Soumitra Ghosh - San Diego CA, US
Robert Davis - San Diego CA, US
Andrew Granston - San Diego CA, US

Assignee:

MIGENIX Corp. - San Diego CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 31/365

US Classification:

514450000

Abstract:

The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

US Patent:

20120095063, Apr 19, 2012

Filed:

Apr 17, 2010

Appl. No.:

13/264935

Inventors:

Francisco Villareal - Chula Vista CA, US
Pam R. Taub - Rancho Santa Fe CA, US
Alan S. Maisel - Solana Beach CA, US
George F. Schreiner - Los Altos Hills CA, US
Anne Murphy - Encinitas CA, US
Katrina Yamazaki - Diamond Bar CA, US
Guillermo Ceballos - Lindavista, MX

International Classification:

A61K 31/353
A61P 3/00
A61P 9/12
A61P 13/12
A61P 7/00
A61P 9/04
A61P 3/04
A61P 5/48
A61P 21/00
A61K 31/4406
A61P 25/28

US Classification:

514355, 514456

Abstract:

The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to stimulate mitochondrial function in cells. The methods and compositions described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.